mitoxantrone has been researched along with Invasiveness, Neoplasm in 14 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this study was to evaluate the efficacy of combined therapy using the cyclooxygenase inhibitor, piroxicam, and mitoxantrone against a relevant canine model of human invasive bladder cancer." | 3.72 | Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. ( Bravo, L; Chun, R; Dernell, WS; Henry, CJ; Higginbotham, ML; Jorgensen, L; Madewell, BR; McCaw, DL; Scott, MA; Sheafor, S; Straw, RC; Turnquist, SE; Tyler, JW, 2003) |
| "Castration-resistant prostate cancer (CRPC) has historically presented significant challenges to both clinicians and patients in regard to disease progression and consequent management." | 2.49 | Challenges in treating advanced disease. ( Petrylak, DP, 2013) |
| "Non muscle invasive bladder cancer, given its high tendency to recur, coupled with an ever-present possibility to progress to potentially life-threatening muscle-invasive disease, remains a challenging clinical problem." | 2.44 | New therapeutical approaches for non muscle invasive bladder cancer. ( Bassi, P; Bongiovanni, L; Cappa, E; D'Agostino, D; Gardi, M; Pinto, F; Racioppi, M; Sacco, E; Totaro, A; Volpe, A, 2008) |
| "We have identified CICs in a human breast cancer cell line, MX-1, and developed a xenograft model in SCID mice." | 1.42 | Differential remodeling of extracellular matrices by breast cancer initiating cells. ( Chen, CS; Raja, AM; So, PT; Sun, W; Tai, DC; Welsch, RE; Xu, S; Yu, H; Zhuo, S, 2015) |
| "With prostate cancer (PCa), circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) portend a poor clinical prognosis." | 1.40 | Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. ( Bergan, RC; Pavese, JM, 2014) |
| "We report a rare case of adult T cell leukemia/lymphoma (ATLL) in which cardiac invasion was clinically demonstrated and treated effectively." | 1.28 | [Cardiac invasion of ATLL cells and therapeutic effects of local along with systemic treatments]. ( Imoto, S; Ito, M; Nakagawa, T, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Noguchi, R | 1 |
| Yoshimatsu, Y | 1 |
| Ono, T | 1 |
| Sei, A | 1 |
| Hirabayashi, K | 1 |
| Ozawa, I | 1 |
| Kikuta, K | 1 |
| Kondo, T | 1 |
| Gourd, E | 1 |
| Petrylak, DP | 1 |
| Pavese, JM | 1 |
| Bergan, RC | 1 |
| Raja, AM | 1 |
| Xu, S | 1 |
| Zhuo, S | 1 |
| Tai, DC | 1 |
| Sun, W | 1 |
| So, PT | 1 |
| Welsch, RE | 1 |
| Chen, CS | 1 |
| Yu, H | 1 |
| Le Coz, V | 1 |
| Zhu, C | 1 |
| Devocelle, A | 1 |
| Vazquez, A | 1 |
| Boucheix, C | 1 |
| Azzi, S | 1 |
| Gallerne, C | 1 |
| Eid, P | 1 |
| Lecourt, S | 1 |
| Giron-Michel, J | 1 |
| Volpe, A | 1 |
| Racioppi, M | 1 |
| Sacco, E | 1 |
| Bongiovanni, L | 1 |
| D'Agostino, D | 1 |
| Cappa, E | 1 |
| Pinto, F | 1 |
| Gardi, M | 1 |
| Totaro, A | 1 |
| Bassi, P | 1 |
| Hogg, ME | 1 |
| Popowich, DA | 1 |
| Wang, EC | 1 |
| Kiel, KD | 1 |
| Stryker, SJ | 1 |
| Halverson, AL | 1 |
| Zinzani, PL | 1 |
| Gandolfi, L | 1 |
| Broccoli, A | 1 |
| Argnani, L | 1 |
| Fanti, S | 1 |
| Pellegrini, C | 1 |
| Stefoni, V | 1 |
| Derenzini, E | 1 |
| Quirini, F | 1 |
| Baccarani, M | 1 |
| Henry, CJ | 1 |
| McCaw, DL | 1 |
| Turnquist, SE | 1 |
| Tyler, JW | 1 |
| Bravo, L | 1 |
| Sheafor, S | 1 |
| Straw, RC | 1 |
| Dernell, WS | 1 |
| Madewell, BR | 1 |
| Jorgensen, L | 1 |
| Scott, MA | 1 |
| Higginbotham, ML | 1 |
| Chun, R | 1 |
| Tokar, M | 1 |
| Rogachev, B | 1 |
| Levi, I | 1 |
| Yerushalmi, R | 1 |
| Ariad, S | 1 |
| Geffen, DB | 1 |
| Oudard, S | 1 |
| Banu, E | 1 |
| Beuzeboc, P | 1 |
| Voog, E | 1 |
| Dourthe, LM | 1 |
| Hardy-Bessard, AC | 1 |
| Linassier, C | 1 |
| Scotté, F | 1 |
| Banu, A | 1 |
| Coscas, Y | 1 |
| Guinet, F | 1 |
| Poupon, MF | 1 |
| Andrieu, JM | 1 |
| Mimeault, M | 1 |
| Mehta, PP | 1 |
| Hauke, R | 1 |
| Henichart, JP | 1 |
| Depreux, P | 1 |
| Lin, MF | 1 |
| Batra, SK | 1 |
| Imoto, S | 1 |
| Nakagawa, T | 1 |
| Ito, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)[NCT03737370] | Phase 1 | 25 participants (Anticipated) | Interventional | 2018-01-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mitoxantrone and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Challenges in treating advanced disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III | 2013 |
New therapeutical approaches for non muscle invasive bladder cancer.
Topics: Antineoplastic Agents; Humans; Hyaluronic Acid; Immunotherapy; Mitoxantrone; Neoplasm Invasiveness; | 2008 |
2 trials available for mitoxantrone and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Addition of mitoxantrone and prednisone to ADT.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2018 |
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2005 |
10 other studies available for mitoxantrone and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor.
Topics: Adult; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Collagen Type VI; Female; Gefiti | 2021 |
Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Survival; D | 2014 |
Differential remodeling of extracellular matrices by breast cancer initiating cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Co | 2015 |
IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferati | 2016 |
HIV and anal cancer outcomes: a single institution's experience.
Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan | 2009 |
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Murine-Derived; Anti | 2011 |
Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Disease Models, Animal; Dogs; Female; | 2003 |
Rituximab in a patient with acute renal failure due to B-cell lymphomatous infiltration of the kidneys.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineop | 2004 |
Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB | 2007 |
[Cardiac invasion of ATLL cells and therapeutic effects of local along with systemic treatments].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Heart Neoplasms; Humans; Ifosfami | 1989 |